State Street SPDR S&P Biotech ETF
XBIDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 24, 2026 | $0.14 | 2026-06-22 | 2026-06-22 |
| December 24, 2025 | $0.41 | 2025-12-22 | 2025-12-22 |
| September 24, 2025 | $0.03 | 2025-09-22 | 2025-09-22 |
| June 25, 2025 | $0.01 | 2025-06-23 | 2025-06-23 |
| March 26, 2025 | $0.01 | 2025-03-24 | 2025-03-24 |
Dividends Summary
- Consistent Payer: State Street SPDR S&P Biotech ETF has rewarded shareholders with 47 dividend payments over the past 19 years.
- Total Returned Value: Investors who held XBI shares during this period received a total of $5.90 per share in dividend income.
- Latest Payout: The most recent dividend of $0.14/share was paid 24 days ago, on June 24, 2026.
- Yield & Schedule: XBI currently pays dividends quarterly with an annual yield of 0.38%.
- Dividend Growth: Since 2007, the dividend payout has grown by 1.1%, from $0.14 to $0.14.
Company News
The Fidelity MSCI Health Care Index ETF (FHLC) offers broad healthcare sector exposure with lower costs (0.08% expense ratio), higher dividend yield (1.3%), and lower volatility, making it suitable for conservative investors. The State Street SPDR S&P Biotech ETF (XBI) focuses on biotechnology with higher growth potential (89.3% 1-year return) bu...
The healthcare sector, down 3.8% year-to-date and the worst performer among S&P 500 sectors, presents selective opportunities despite weak aggregate earnings growth. While the sector faces headwinds with the lowest forward profit margins and weakest 2026 EPS growth outlook, specific subsectors show promise: Pharmaceuticals are rerating as GLP-1 e...
The Vanguard Health Care ETF (VHT) offers broader healthcare sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.69%), while the SPDR S&P Biotech ETF (XBI) provides targeted biotech exposure with higher volatility but stronger recent 1-year returns (62.20% vs 13.00%). VHT is better suited for income-seeking investo...
Major pharmaceutical companies face a patent cliff with $175 billion in annual drug sales losing exclusivity over the next six years, prompting increased M&A activity. Two biotech ETFs—SPDR S&P Biotech (XBI) and iShares Biotechnology (IBB)—offer investors exposure to capitalize on industry volatility and potential winners from consolidation.
Nextech Invest, a Switzerland-based biotech-focused fund, increased its stake in Relay Therapeutics by 855,097 shares (~$6.1 million). The purchase brings Relay to 3.85% of Nextech's portfolio. Relay's stock has surged 197% over the past year, driven by its computational drug discovery platform and clinical-stage pipeline including lead candidate...
